A 4-part, open-label, multicenter, multinational study of the safety, tolerability,pharmacokinetics, pharmacodynamic, and exploratory efficacy of venglustat incombination with Cerezyme in adult patients with Gaucher disease Type 3 withvenglustat monotherapy extension - PDY13949

Genzyme Corp.0 个研究点目标入组 18 人开始时间: 2023年11月10日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方: Genzyme Corp.
入组人数: 18

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 64（—）
性别: All

入选标准

•GD1 participant is =18 and =40 years of age., -Participant is willing to abstain from consumption of grapefruit, grapefruit juice, or grapefruit containing products for 72 hours prior to administration of the first dose of venglustat and for the duration of the treatment period., -Oculomotor apraxia characterized by a horizontal saccade abnormality., -Female participants of childbearing potential and male patients must be willing to practice true abstinence in line with their preferred and usual lifestyle, or use 2 acceptable effective methods of contraception for the duration of the study and for at least 6 weeks for females and 90 days for males following their last dose of venglustat., -GD3 participant is =18 years of age., -Participant must provide written informed consent prior to any study-related procedures being performed., -Participant has a clinical diagnosis of Gaucher disease Type 1 (GD1) or Gaucher disease Type 3 (GD3) and documented deficiency of acid beta-glucosidase activity confirming this diagnosis., -Participant has received ERT (Cerezyme or other ERT; as deemed appropriate by local regulations) for at least 3 years prior to enrollment, on a stable dose for at least 6 months and is within the therapeutic goals defined below, and is deemed clinically stable for at least 1 year by the Investigator., -Participant has reached Gaucher disease therapeutic goals defined as all of the following to be eligible for this study: -Hemoglobin level of =11.0 g/dL for females and =12.0 g/dL for males. -Platelet count =100,000/mm3. -Spleen volume <10 multiples of normal (MN), or total splenectomy (provided the splenectomy occurred >3 years prior to randomization). -Liver volume <1.5 MN. -No bone crisis and free of symptomatic bone disease such as bone pain attributable to osteonecrosis and/or pathological fractures within 3 months prior to screening., -Participant has maintained GD therapeutic goals defined as all of the following to be eligible for entering Part 4 of this study: -Hemoglobin level of =11.0 g/dL for females and =12.0 g/dL for males -Platelet count =100 000/mm3 -Spleen volume <10 multiples of normal (MN), or total splenectomy -Liver volume <1.5 MN -No bone crisis and free of symptomatic bone disease such as bone pain attributable to osteonecrosis and/or pathological fractures within 3 months prior to entering Part 4, -Participant, if female and of childbearing potential, must have a negative pregnancy test [urine beta-human chorionic gonadotropin (ß-hCG)] at baseline., -If participant has a history of seizures, except for myoclonic seizures, they are well controlled under appropriate medication not identified as a strong or moderate inducer or inhibitor of cytochrome P450 (CYP) 3A.

排除标准

•-Participant has myoclonic seizures., -Participant has had a major organ transplant (e.g., bone marrow or liver)., -Substrate reduction therapy or chaperone therapy for GD within 6 months prior to enrollment., -Participant, in the opinion of the investigator, is unable to adhere to the requirements of the study or unable to undergo study assessments (e.g., contraindications for magnetic resonance imaging)., -Participant has had a partial or total splenectomy within 3 years prior to randomization., -Participant is blood transfusion-dependent., -Prior esophageal varices or liver infarction or current liver enzymes (alanine aminotransferase [ALT]/ aspartate aminotransferase [AST]) or total bilirubin >2 times the upper limit of normal, unless the patient has a diagnosis of Gilbert Syndrome., -Participant has any clinically significant disease, other than GD, including cardiovascular (congenital cardiac defect, coronary artery disease, valve disease or left sided heart failure; clinically significant arrhythmias or conduction defect), hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic (eg, hypokalemia, hypomagnesemia) or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may preclude participation., -Participant has renal insufficiency, as defined by an estimated glomerular filtration rate <30 mL/min/1.73m2 at the screening visit., -Participant has received an investigational product within 30 days prior to enrollment., -Participant has a history of cancer, with the exception of basal cell carcinoma., -Participant is pregnant or lactating., -Participant has, according to World Health Organization (WHO) Grading, a cortical cataract > one-quarter of the lens circumference (Grade cortical cataract-2) or a posterior subcapsular cataract >2 mm (Grade posterior subcapsular cataract-2). Patients with nuclear cataracts will not be excluded., -Participant requires use of invasive ventilatory support., -Participant requires use of noninvasive ventilator support while awake for longer than 12 hours daily., -Participant is unable to receive treatment with Cerezyme due to a known hypersensitivity or is unwilling to receive Cerezyme treatment to ensure maintenance of Gaucher treatment goals., -Participant is currently receiving potentially cataractogenic medications (corticosteroids, psoralens used in dermatology with ultraviolet light therapy [PUVA], typical antipsychotics, and glaucoma medications) or any medication that may worsen the vision of a patient with cataract (eg, alphaadrenergic glaucoma medications)., -Participant has received strong or moderate inducers or inhibitors of CYP3A within 15 days or 5 half-lives from screening, whichever is longer, prior to enrolment in Part 2. This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting venglustat administration in Parts 2 and 3., -Participant is scheduled for in-patient hospitalization including elective surgery, during the study.

研究者

发起方

Genzyme Corp.

相似试验

进行中（未招募）

1 期

Venglustat in Combination with Cerezyme in Adult Patients with GaucherDisease Type 3 with venglustat monotherapy extensioGaucher disease

EUCTR2014-002550-39-DEGenzyme Corporation18

进行中（未招募）

1 期

A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme (galsulfase) in Infants with Maroteaux-Lamy Syndrome (MPS VI) - N/AMucopolysaccharidosis Type VI (MPS VIMaroteaux-Lamy Syndrome)MedDRA version: 6.0Level: PTClassification code 10056892

EUCTR2005-003512-30-FRBioMarin Pharmaceutical Inc.4

进行中（未招募）

不适用

EUCTR2005-003512-30-PTBioMarin Pharmaceutical Inc4

进行中（未招募）

1 期

A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-302 (BRAVO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis -aquinimod is developed for the treatment of relapsing remitting multiple sclerosis.MedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosis

EUCTR2009-015815-42-SKTeva Pharmaceutical Industries Ltd1,245

进行中（未招募）

1 期

A clinical study in subjects with multiple sclerosis who successfullycompleted the MS-LAQ-301 (ALLEGRO) study, to assess the safety oflaquinimod (experimental drug) when taken for a long period of time andhow it affects the course of the disease.aquinimod is developed for the treatment of relapsing remitting multiple sclerosis.MedDRA version: 19.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders

EUCTR2009-012989-30-EETeva Pharmaceutical Industries Ltd542